Trial reportOpen forum infectious diseases2025
Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial.
Trial report in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03684044 (A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza
Who cites it
6 citing papers in PubMed.
- Antiviral Resistance Associated With Multiple Mutations Occurring in Seasonal Influenza A(H3N2) Virus in a Patient Treated With Oseltamivir.Clinical case reports · 2026Article
- Influenza.Nature reviews. Disease primers · 2026Review
- A Sequence-Based Update on Amino Acid Substitutions in Influenza Polymerase Acidic Protein in Europe That Alter Baloxavir Susceptibility From 2009 to 2025.Influenza and other respiratory viruses · 2026Article
- Antiviral Resistance in Influenza: Clinical and Public Health Implications.Influenza and other respiratory viruses · 2026Review
- Use of baloxavir as adjunctive antiviral therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with influenza.Antimicrobial agents and chemotherapy · 2026Article
- Clinical practice guidelines for the treatment and prophylaxis of influenza in China (2025 edition).Infectious diseases & immunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Combining baloxavir with neuraminidase inhibitors (NAIs) has not demonstrated significant benefits in severe influenza. High-risk populations with impaired viral clearance may represent the optimal candidates for this combination treatment. Methods: We conducted a post hoc analysis of the Flagstone trial (NCT03684044), including patients hospitalized with severe influenza. Eligible participants met at least 1 of the following criteria: immunosuppression, diabetes, or chronic lung disease. Time to clinical improvement (TTCI), 28-day mortality, virological outcomes, and safety end points were assessed. Results: Among the 143 patients included in the efficacy analysis, 92 received baloxavir in combination with NAI (dual antiviral group), while 51 received NAIs alone (mono antiviral group). The median TTCI did not differ significantly between groups ( Conclusions: The combination of baloxavir and NAI demonstrated superior mortality reduction compared with NAI monotherapy, without increasing the risk of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.